Navigation Links
Cobalis Corp. Announces Second Update Conference Call for Investors on October 5, 2010
Date:9/28/2010

IRVINE, Calif., Sept. 28 /PRNewswire-FirstCall/ -- Cobalis Corp. (Pink Sheets: CLSC) is holding the second Investor Update Conference Call to provide investors and shareholders with further details and the latest updates about a range of important securities, financial and legal issues.

Shareholders and investors MUST RSVP to participate in this conference call, to be held Tuesday, October 5, 2010 at 1:15pm Pacific Time. Interested parties may RSVP to participate in the call by contacting Cobalis at (949) 260-0123 between 9:00 am and 5:00 pm Pacific Time, Monday through Friday, to get the conference call dial-in number and passcode.

The agenda of this call will include: Financial status and private funding; details of current legal and corporate issues; update on the recent SEC complaint and resolution; resumption of trading; launch update; current legal settlements and how the Company is meeting the terms of its agreements; overview of additional revenue opportunities; what happened with previously planned product release dates.

There will also be a Question and Answer opportunity as well as opportunities following the Conference Call for one-on-one discussions with interested parties.

FORWARD LOOKING STATEMENTS

Cobalis Corp., expectation of results and other forward-looking statements contained in this email involve a number of risks and uncertainties. Among the factors that could cause actual results to differ materially from those expected are the following: business conditions and general economic conditions; competitive factors, such as pricing and marketing efforts; and the pace and success of product research and development. These and other factors may cause expectations to differ.

ABOUT COBALIS CORP—PREHISTIN®

Cobalis Corp. is a specialty pharmaceutical, nutraceutical and preventive healthcare product development and marketing company. Its flagship product, PreHistin® Allergy Defense Formula, The World's FIRST Pre-Histamine, is designed to mitigate overproduction of IgE levels and restore a normal response to seasonal and year-round indoor and outdoor allergens. PreHistin® is available without prescription for both long-term and daily use.

For PreHistin® product information and ordering please visit at www.PreHistin.com or call toll free 1-877-4POLLEN. For additional company information please visit the corporate website at www.Cobalis.com CONTACT:Chas Radovich, PresidentCobalis Corp.949-260-0123info@cobalis.com
'/>"/>

SOURCE Cobalis Corp.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Cobalis Corp. Provides Marketing Update Conference Call for Investors
2. CellCyte Genetics Corp. Enters Collaborative Research Agreement With Cleveland Clinic Foundation to Qualify Stem Cell Delivery in Damaged Heart Tissue
3. Cantel Medical Corp.s Crosstex Subsidiary Addresses School MRSA Concerns With SaniTyze(TM) Brand Hand Sanitizer and Sanitex(R) Surface Disinfecting Line of Products
4. Alliance Pharmaceutical Corp. Updates Oxygent(TM) Clinical Development Plan
5. Raptor Pharmaceuticals Corp. Initiates Phase IIa Clinical Study for Convivia(TM)
6. Alliance Pharmaceutical Corp. Announces Approval of Proposed Actions at Annual Shareholders Meeting
7. BioSpecifics Technologies Corp. Announces Initiation of Phase IIb Trial for Peyronies Disease
8. Raptor Pharmaceuticals Corp. Announces Positive Phase IIa Clinical Study Results for Convivia(TM) Program
9. BioSpecifics Technologies Corp. to Present at Cowen and Company 29th Annual Health Care Conference
10. BioSpecifics Technologies Corp. Announces XIAFLEX(TM) CORD I Study Published in New England Journal of Medicine
11. Raptor Pharmaceuticals Corp. and TorreyPines Complete Merger
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... Ill. and INDIANAPOLIS , ... students receiving a Lilly Diabetes Tomorrow,s Leaders Scholarship is ... 2016 scholarship winners, announced today online at www.diabetesscholars.org ... let type 1 diabetes stand in the way of ... has supported the Foundation,s scholarship program since 2012, and ...
(Date:6/23/2016)... -- The vast majority of dialysis patients currently receive ... usually 3 times a week, with treatment times averaging ... equipment preparation and wait time.  This regimen can be ... who are elderly and frail.  Many elderly dialysis patients ... for some duration of time. Residents in ...
(Date:6/23/2016)... WASHINGTON , June 23, 2016  The ... Pharmaceuticals has joined the health policy research organization ... Steven Romano , MD, senior vice president and ... his company,s representative on the NPC Board of ... are pleased that Mallinckrodt has joined us in ...
Breaking Medicine Technology:
(Date:6/24/2016)... , ... June 24, 2016 , ... Global law firm ... 2016 Legal Elite. The attorneys chosen by their peers for this recognition are considered ... Seven Greenberg Traurig Shareholders received special honors as members of this year’s Legal Elite ...
(Date:6/24/2016)... Plano, TX (PRWEB) , ... June 24, 2016 , ... ... taking part in Genome magazine’s Code Talker Award, an essay contest in which patients ... for an award to be presented at the 2016 National Society of Genetic Counselors ...
(Date:6/24/2016)... ... June 24, 2016 , ... Strategic Capital Partners, ... economy by obtaining investment capital for emerging technology companies. SCP has delivered ... already resulted in more than a million dollars of capital investment for five ...
(Date:6/24/2016)... ... June 24, 2016 , ... Advanced Plastic Surgery Institute ... pageant as its official Medspa Sponsor. Dr. Josh Olson, a board-certified plastic surgeon, ... , Dr. Olson says the decision to support the pageant in an official ...
(Date:6/24/2016)... ... 24, 2016 , ... Today, InhaleLabs.com (Inhale) offilially launched its site, ... matching users with high quality water pipes within an ideal price range. The site ... was founded by two brothers, Nick and Mike Hunter, who use medical cannabis to ...
Breaking Medicine News(10 mins):